LAGUNA BEACH, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTC:CLSC - News), a pharmaceutical biotech Company specializing in the development of anti-allergy medications, today announced the planned marketing launch of the flagship anti-allergy product PreHistin™ after approval in Federal Court in Santa Ana, CA on Jan. 13, 2009. The launch of PreHistin™ is scheduled for February 2009, and will enable the company to be discharged from Chapter 11.
Related Quotes
Symbol Price Change
CLSC.PK 0.08 0.00
Chart for COBALIS CORP NEW
{\"s\" : \"clsc.pk\",\"k\" : \"c10,l10,p20,t10\",\"o\" : \"\",\"j\" : \"\"}
Cobalis Corp. has conducted numerous clinical trials in over 30 board certified clinics with physicians throughout the U.S. with over 2200 patients in the Phase III trials of PreHistin™. The Company has demonstrated that pre seasonal treatment with PreHistin™ was seen to clearly reduce allergy symptoms without causing any side effects. The data from the clinical trials will enable Cobalis to launch PreHistin™ as a nutraceutical with clinical claims.
Cobalis Corp. has a manufacturing agreement with Monarch Nutraceuticals, a division of Nutraceutical Corp. (Nasdaq: NUTR - News) in Ogden, Utah, to manufacture and produce PreHistin™. Nutraceutical Corp. is the original manufacturer of PreHistin™ under the name Alleratin, which was distributed to thousands of allergy sufferers at no charge for compassionate use.
Chas Radovich, the CEO of Cobalis, said, “We are extremely proud to have reached the milestone of being able to launch PreHistin™, our flagship product in February 2009. The product will be available to the general public and to over 10,000 previous PreHistin™ users from the Phase III trials and allergy suffers who received compassionate use product over the years.” Mr. Radovich went on to say, “We will finally be able to get our products to the over 50,000,000 allergy sufferers in the United States who have been waiting for a natural alternative to treat or prevent allergies.” |
